key: cord-0969254-ks0wll86
authors: Bricker, Traci L.; Darling, Tamarand L.; Hassan, Ahmed O.; Harastani, Houda H.; Soung, Allison; Jiang, Xiaoping; Dai, Ya-Nan; Zhao, Haiyan; Adams, Lucas J.; Holtzman, Michael J.; Bailey, Adam L.; Case, James Brett; Fremont, Daved H.; Klein, Robyn; Diamond, Michael S.; Boon, Adrianus C.M.
title: A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
date: 2021-06-29
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109400
sha: df4eda9832aea42d8c49462e92bedf5af2a862dd
doc_id: 969254
cord_uid: ks0wll86

The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable of neutralizing the virus, antibody levels in serum were higher in hamsters vaccinated by an intranasal compared to intramuscular route. Accordingly, against challenge with SARS-CoV-2, ChAd-SARS-CoV-2-S immunized hamsters were protected against less weight loss and had reduced viral infection in nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated a global pandemic more severe disease, mimicking COVID-19 in humans (Osterrieder et al., 2020) . In hamsters, 55 SARS-CoV-2 primarily infects the upper and lower respiratory tracts, although viral RNA and 56

antigen has been detected in other tissues (e.g., intestines, heart, and olfactory bulb). The peak 57 of virus replication occurs between days 2 and 3 post infection (dpi) and is cleared by 14 dpi in 58 surviving animals. Histopathological analysis of infected hamsters shows multifocal interstitial 59 pneumonia characterized by pulmonary consolidation starting as early as 2 dpi. Inflammation is 60 associated with leukocyte infiltration, comprised primarily of macrophages and neutrophils, and Fig S3) . No changes in 148 the expression of Cxcl10, Ddx58, or Ccl3 were observed in either the lung or muscle in either 149 group (Fig S3) . 150

CoV-2 challenge. We next evaluated the protective effect of the ChAd vaccines in the hamster 152 SARS-CoV-2 challenge model. Golden Syrian hamsters immunized with ChAd-SARS-CoV-2-S 153 or ChAd-control were challenged IN with 2.5 x 10 5 PFU of SARS-CoV-2, and 2 dpi a nasal swab 154 was collected for viral burden analysis by qPCR and plaque assay. The N-gene copy number in 155 the ChAd-control immunized animals was ~10 9 copies per mL in both the IM and IN control 156 groups (Fig 3A) . Immunization with ChAd-SARS-CoV-2-S reduced the N-gene copy number by 157 100-fold in the IN (10 7 /mL) and 10-fold in the IM (10 8 /mL) immunized animals (P < 0.0001 and P 158 < 0.001 respectively, Fig 3A) . N-gene copy number was significantly lower in the IN than IM 159 immunized animals (P < 0.05, Fig 3A) . At 2 dpi, infectious virus was detected by plaque assay 160 in 4 of 20 ChAd-SARS-CoV-2-S-immunized animals and 15 of 20 ChAd-control immunized 161 animals (Fig 3B) . At 3 dpi, six hamsters per group were sacrificed, and lungs were collected for 162 viral burden analysis (left lobe) by qPCR or FFA, or for histology (other lung lobes). In the 163 control groups, we detected 10 9 -10 10 copies of N-gene per mg of lung homogenate, and the 164 mean infectious titer was 6 x 10 4 FFU/mL. No difference was observed between the two control 165 groups. Immunization with ChAd-SARS-CoV-2-S vaccine significantly reduced the N-gene copy 166 number (P < 0.01, Fig 3C) and infectious titer in both the IN and IM immunized group (Fig 3D) . 167

A comparison between IN and IM immunization revealed significantly lower N-gene copies per 168 mg (788-fold, P < 0.01, Fig 3C) , but not in infectious virus titer (P = 0.5, Fig 3D) , in the lungs of 169 IN immunized animals. The remaining four animals per group were monitored for weight loss for 170 10 days. The ChAd-control immunized animals lost an average of 4% and 8% of their starting 171 body weight (Fig 3E) . Immunization with ChAd-SARS-CoV-2-S attenuated weight loss after 172 SARS-CoV-2 challenge in both groups (P < 0.01, Fig 3E) , with a possibly greater effect 173 J o u r n a l P r e -p r o o f following IN immunization. To assess if the ChAd-SARS-CoV-2-S vaccine induced sterilizing 174 immunity by either of the immunization routes, we collected the serum 10 dpi to test for the 175 presence of antibodies against recombinant NP by ELISA. A robust anti-NP IgG(H+L) (Fig S4)  176 and IgG2/3 (Fig 3F) antibody response was detected in all ChAd-control and ChAd-SARS-CoV-177 2-S immunized animals. 178

Immunization with Chimpanzee Ad-vectored vaccine minimizes lung pathology in 179 hamsters. To support these findings, we performed RNA in situ hybridization (RNA-ISH) and H 180 & E staining on sections from formalin-fixed lung tissues from immunized hamsters. RNA-ISH 181 detected viral RNA in all animals immunized with ChAd-control vaccine (Fig 4A-B and Fig S5) . 182

On average, ~20% of the section was positive for SARS-CoV-2 RNA. The presence of viral 183 RNA was associated with inflammation, tissue damage, and bronchopneumonia, as evidenced 184 by immune cell infiltration around bronchioles, alveolar edema, fluid exudates, and 185 intraparenchymal hemorrhage (Fig S5) . In contrast, sections from animals immunized IM with 186

ChAd-SARS-CoV-2-S contained no or few SARS-CoV-2 positive cells by RNA-ISH and 187 inflammation was greatly reduced (P < 0.01, Fig 4A-B and Fig S6) . No SARS-CoV-2 positive 188 cells were detected following IN immunization with ChAd-SARS-CoV-2-S (P < 0.01, Fig 4A-B  189 and Fig S6) . and cellular debris was further reduced (Fig 4D) . Collectively, these studies show that the (Table S1 ). Compared to five naïve animals, expression of 8/20 inflammatory host 212 genes (Ccl2, Ccl3, Cxcl10, Ddx58, Ifit3, IL10, IL12p40, and Irf7 increased > 2-fold in the ChAd-213

Control immunized and SARS-CoV-2 challenged animals (Fig 5A) . A significant increase in 214 gene-expression was observed for Ccl3, Ifit3, Cxcl10, and Irf7 in both ChAd-Control-IN and 215

ChAd-Control-IM animals (P < 0.05, Fig 5A) . ChAd-SARS-CoV-2-S immunization significantly 216 reduced inflammatory gene expression after SARS-CoV-2 challenge (Fig 5B) with the 217 expression of a subset of host genes, such as Ccl5, Ccl3 and Cxcl10, near normal levels. A 218 comparison in host gene expression between IM and IN immunization identified Irf7 and Ifit3 as 219 two host genes whose expression was significantly (P < 0.01) lower in the IN compared to IM 220 immunized animals (Fig 5B) . These data suggest that IN delivery of the ChAd-vectored SARS- The reason for the higher antibody responses after IN versus IM immunization currently is 246 not known. Spike gene expression three days after IN or IM immunization was similar in the 247 lung and muscle tissue respectively, suggesting that the amount of spike protein produced is 248 equal between the two sites. IN immunization also did not induce a more robust innate immune 249 response, associated with stronger adaptive immune responses, compared to IM immunization. interleukins (IL-10 is an exception), TNF-α, and complement factors did not increase after 304

infection. This lack of expression may be due to the time of organ collection (3 dpi), when the 305 inflammatory response is still developing. The lack of IFN-γ could be explained by the increase 306 in IL-10 expression or the early time point evaluated that precedes influx of NK cells and 307

Correlates of immune protection and SARS-CoV-2 associated disease were investigated in 309 our cohort of hamsters. Virus neutralization in serum correlated better with RBD-specific 310 antibody levels (r = 0.83, P < 0.0001) than S-protein specific responses (r = 0.31, P > 0.05, Fig  311   S7 ). Of the three humoral response parameters, the virus neutralization serum titer (FRNT, IC 50 ) 312 correlated best with weight loss 3 dpi (r = 0.59, P < 0.0001, Fig S7) . Weight loss at 3 dpi was 313 strongly associated with viral RNA levels (r = -0.68, P < 0.001) and infectious virus load (r = - CoV-2 infected hamsters sacrificed at different time points after inoculation (n = 5 for 2 dpi, n = 3 373 for 3 dpi, n = 3 for 4 dpi, n = 5 for 5 dpi, n = 2 for 8 dpi, n = 3 for 14 dpi, n = 3 for uninfected). 

Further information and requests for resources and reagents should be directed to the Lead 433

Contact, Adrianus C.M. Boon (jboon@wustl.edu). 434

All requests for resources and reagents should be directed to the Lead Contact author. This 436 includes viruses, vaccines, and primer-probe sets. All reagents will be made available on 437 request after completion of a Materials Transfer Agreement. 438

All data supporting the findings of this study are available within the paper and are available 440 from the corresponding author upon request. This paper does not include original code. Any 441 additional information required to reanalyze the data reported in this paper is available from the 442 lead contact upon request. Plaque assays were performed on Vero E6 cells in 24-well plates. Nasal swabs or lung 522 tissue homogenates were serially diluted 10-fold, starting at 1:10, in cell infection medium 523 (DMEM + 2% FBS + L-glutamine + penicillin + streptomycin). Two hundred and fifty microliters 524 of the diluted virus were added to a single well per dilution per sample. After 1 h at 37°C, the 525 inoculum was aspirated, the cells were washed with PBS, and a 1% methylcellulose overlay in 526 MEM supplemented with 2% FBS was added. Seventy-two hours after virus inoculation, the 527 cells were fixed with 4% formalin, and the monolayer was stained with crystal violet (0.5% w/v in 528 25% methanol in water) for 1 h at 20°C. The number of plaques were counted and used to 529 calculate the plaque forming units/mL (PFU/mL). 530

To quantify viral load in nasal swabs and lung tissue homogenates, RNA was extracted 531 using RNA isolation kit (Omega). SARS-CoV-2 RNA levels were measured by one-step 532 quantitative reverse transcriptase PCR (qRT-PCR) TaqMan assay as described previously 533 J o u r n a l P r e -p r o o f recommendations. Lung slides were scanned using the Hamamatsu NanoZoomer slide 579 scanning system and head sections were imaged using the Zeiss AxioImager Z2 system. Lung 580 sections were scored according to a previous publication (Imai et al., 2020) (<10% affected lung 581 tissue = 1, >10% but <50% affected area = 2, >50% affected area = 3). and Tnfa and results were normalized to Rpl18 and B2m levels. The primers and probes were 590 derived from previous publications (Zivcec et al., 2011) or developed in-house (see Table S1 ). 591

Fold change was determined using the 2-∆∆Ct method comparing immunized and SARS-CoV-2 592 challenged hamsters to naïve controls. 593

Statistical significance was assigned when P values were < 0.05 using GraphPad Prism version Changes in functional parameters or immune parameters were compared to isotype-treated 599 animals and were analyzed by one-way ANOVA with Sidak, Dunnett's or Bonferonni test for 600 multiple comparisons. We used a Pearson correlation analysis to immune correlates of vaccine-601 mediated protection SARS-CoV-2. 602

STAT2 signaling restricts viral dissemination but drives 605 severe pneumonia in SARS-CoV-2 infected hamsters

COVID-19 case-fatality rate and demographic and 607 socioeconomic influencers: worldwide spatial regression analysis based on country-level data

Simulation of the clinical and pathological manifestations of Coronavirus Disease

Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper 615 respiratory SARS-CoV-2 entry and replication

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and 618 serum-derived polyclonal antibodies

Animal models of mechanisms of SARS-CoV-2 infection and COVID-621 19 pathology

An interactive web-based dashboard to track COVID-19 in real 623 time

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

A single-dose live-attenuated YF17D-629 vectored SARS-CoV2 vaccine candidate

An 631 adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus 632 macaques

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower 635 Respiratory Tracts against SARS-CoV-2

Syrian hamsters as a small animal model for SARS-CoV-2 638 infection and countermeasure development

Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained 641 and protective immunity against MERS-CoV infection

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a 644 weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

Favipiravir at high doses has potent antiviral 647 activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human 651 immunodeficiency virus vaccine and localization in the central nervous system

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5

Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from 655 Fatal MERS-CoV Infection

Recent progress in mucosal vaccine development: potential and limitations

A systematic review and meta-analysis of published 659 research data on COVID-19 infection fatality rates

Predictors of COVID-19 severity: a systematic review 662 and meta-analysis

Animal models for COVID-19

Age-Dependent Progression of SARS-CoV-2 Infection in 668 Syrian Hamsters

Animal Models for 670 SARS-CoV-2 research: A Comprehensive Literature Review. Transboundary and emerging diseases

Haemagglutinin stability was 672 not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against 673 A/H1N1pdm09 viruses in the

Airway delivery of an adenovirus

Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates

Hydroxychloroquine prophylaxis and treatment is 679 ineffective in macaque and hamster SARS-CoV-2 disease models

Defining the Syrian hamster as a highly susceptible preclinical model 682 for SARS-CoV-2 infection

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a 688 cost-effective inactivated SARS-CoV-2 vaccine

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in 691 hamsters

A single dose of ChAdOx1 MERS provides 694 protective immunity in rhesus macaques

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza 697 vaccines in humans

A single dose of recombinant VSV-ΔG-spike vaccine provides protection 700 against SARS-CoV-2 challenge

A highly 702 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Current prospects and future challenges for nasal vaccine delivery

Clinical 707 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective 708 cohort study

Validation of assays to 710 monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)

show that a single intranasal dose of a SARS-CoV-2 vaccine, a chimpanzee adenoviral vector expressing the spike protein, induces neutralizing antibodies and protects Syrian hamsters against SARS-CoV-2 infection in both the upper and lower respiratory tracts